Impact of anti-tumor necrosis factor alpha antibodies administered to pregnant women with inflammatory bowel disease on long-term outcome of exposed children

Inflammatory Bowel Diseases

Volumn 20, Issue 3, 2014, Pages 495-501

  Bortlik, Martin ^a   Duricova, Dana ^a   Machkova, Nadezda ^a   Kozeluhova, Jana ^b   Kohout, Pavel ^c   Hrdlicka, Ludek ^a   Durilova, Marianna ^d   Mitrova, Katarina ^d   Hradsky, Ondrej ^d   Bronsky, Jiri ^d   Malickova, Karin ^a,e   Lukas, Milan ^a,e  

^a CHARLES UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c FAKULTNÍ THOMAYEROVA NEMOCNICE   (Czech Republic)

^d UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^e CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Anti TNF therapy; Children; Immune system; Inflammatory bowel disease; Prenatal exposure

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; CORTICOSTEROID DERIVATIVE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MERCAPTOPURINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ALLERGY; ANTIBIOTIC THERAPY; APHTHOUS STOMATITIS; ARTICLE; ASTHMA; ATOPIC DERMATITIS; BCG VACCINATION; BRONCHITIS; BURN; CELLULAR IMMUNITY; CHICKENPOX; CHILD; CLINICAL ARTICLE; CONJUNCTIVITIS; CONTROLLED STUDY; CYSTITIS; CZECH REPUBLIC; DRUG EFFECT; FEMALE; FOLLOW UP; GASTROENTERITIS; HUMAN; INFLAMMATORY BOWEL DISEASE; INGUINAL HERNIA; LABORATORY TEST; LARYNGITIS; MALE; OUTCOME ASSESSMENT; PEDIATRICIAN; PNEUMONIA; POSTNATAL DEVELOPMENT; PREGNANCY; PREGNANCY OUTCOME; PREGNANT WOMAN; PRENATAL EXPOSURE; PRIORITY JOURNAL; PSYCHOMOTOR DEVELOPMENT; PYELONEPHRITIS; RETROSPECTIVE STUDY; TRACHEOBRONCHITIS; UPPER RESPIRATORY TRACT INFECTION;

ANTIBODIES, MONOCLONAL; CHILD; CHILD, PRESCHOOL; CZECH REPUBLIC; FEMALE; FOLLOW-UP STUDIES; GROWTH DISORDERS; HUMANS; INFANT; INFECTION; INFLAMMATORY BOWEL DISEASES; MALE; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; PROGNOSIS; PSYCHOMOTOR DISORDERS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84897389359     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/01.MIB.0000440984.86659.4f     Document Type: Article

References (15)

1. van der Woude CJ, Kolacek S, Dotan I, et al. European evidenced-based consensus on reproduction in inflammatory bowel disease. J Crohns Colitis. 2010;4:493-510.
2. Bortlik M, Machkova N, Duricova D, et al. Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNFalpha therapy during pregnancy: three-center study. Scand J Gastroenterol. 2013;48:951-958.
3. Marchioni RM, Lichtenstein GR. Tumor necrosis factor-alpha inhibitor therapy and fetal risk: a systematic literature review. World J Gastroenterol. 2013;19:2591-2602.
4. Zelinkova Z, van der Ent C, Bruin K, et al. Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure. Clin Gastroenterol Hepatol. 2013;11:318-321.
5. Mahadevan U, Wolf DC, Dubinsky M, et al. Placental transfer of antitumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11:286-292.
6. Vasiliauskas EA, Church JA, Silverman N, et al. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol. 2006;4:1255-1258.
7. Zelinkova Z, de Haar C, de Ridder L, et al. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther. 2011;33:1053-1058.
8. Mahadevan U, Martin CF, Sandler RS, et al. PIANO: a 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy. Gastroenterology. 2012;142:S149.
9. Slatter MA, Gennery AR. Clinical immunology review series: an approach to the patient with recurrent infections in childhood. Clin Exp Immunol. 2008;152:389-396.
10. Dalal I, Reid B, Nisbet-Brown E, et al. The outcome of patients with hypogammaglobulinemia in infancy and early childhood. J Pediatr. 1998;133:144-146.
11. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol. 2012;107: 1409-1422.
12. Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929-936.
13. Kratenova J, Zejglicova K, Maly M. Allergic disorders in children. Report from the National Institute of Public Health, July 2013, Prague, Czech Republic. Available at http://www.szu.cz/uploads/documents/chzp/alergie/ Subsystem-6-OZ-2013-2.pdf. Accessed December 7, 2013.
14. Cheent K, Nolan J, Shariq S, et al. Case report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease. J Crohns Colitis. 2010;4:603-605.
15. Stehlik J, Mares K, Lukas M, et al. Recommendation for vaccination in patients with Crohn's disease and ulcerative colitis on immunosuppressive and biological therapy. Ces a Slov Gastroent a Hepatol. 2010;64: 40-48.